Published in Eur J Clin Pharmacol on May 11, 2014
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med (2013) 11.14
Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med (2007) 10.87
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29
Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet (2014) 10.06
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med (2003) 6.70
A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med (2002) 5.55
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace (2013) 5.16
Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score. Chest (2013) 4.71
New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology (2013) 4.58
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med (2010) 4.16
Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J (2012) 3.66
Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA (2005) 3.54
Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation (2012) 3.47
The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol (2007) 3.09
Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet (2008) 3.00
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost (2011) 2.87
Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation (2011) 2.80
A specific antidote for dabigatran: functional and structural characterization. Blood (2013) 2.77
Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation (2013) 2.72
Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke (2013) 2.52
Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost (2010) 2.47
Managing oral anticoagulant therapy. Chest (2001) 2.25
Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost (2011) 2.22
Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med (2007) 2.20
Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors. Am J Cardiol (2013) 2.19
Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost (2011) 2.01
Chronic diseases in developing countries: health and economic burdens. Ann N Y Acad Sci (2008) 1.94
Management of atrial fibrillation. BMJ (2009) 1.66
Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis (2012) 1.63
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost (2011) 1.59
Prescribing patterns of novel oral anticoagulants following regulatory approval for atrial fibrillation in Ontario, Canada: a population-based descriptive analysis. CMAJ Open (2013) 1.57
Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). Circ Cardiovasc Qual Outcomes (2010) 1.50
Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. BMJ Open (2013) 1.40
Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost (2008) 1.38
The role of aspirin for stroke prevention in atrial fibrillation. Nat Rev Cardiol (2011) 1.14
Adverse drug reaction reporting in a pharmacovigilance centre of Nepal. Australas Med J (2012) 1.14
Cardiovascular complications in newly diagnosed rheumatic heart disease patients at Mulago Hospital, Uganda. Cardiovasc J Afr (2013) 1.14
Willingness to pay per quality-adjusted life year: is one threshold enough for decision-making?: results from a study in patients with chronic prostatitis. Med Care (2011) 1.06
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart (2012) 1.05
Epidemiological profile of atrial fibrillation: a contemporary perspective. Prog Cardiovasc Dis (2005) 1.04
Improving the outcomes of anticoagulation: an evaluation of home follow-up of warfarin initiation. J Intern Med (2004) 1.04
Review of epidemiology and management of atrial fibrillation in developing countries. Int J Cardiol (2013) 1.04
Management of Chinese patients on warfarin therapy in two models of anticoagulation service - a prospective randomized trial. Br J Clin Pharmacol (2006) 1.02
Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol (2006) 1.01
Childhood pneumonia in developing countries. Lancet Respir Med (2013) 1.01
Prevalence of multidrug resistance among retreatment pulmonary tuberculosis cases in a tertiary care hospital, Hyderabad, India. Lung India (2013) 0.99
Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry. Thromb Haemost (2014) 0.96
Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol (2013) 0.95
An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost (2010) 0.95
Point-of-care monitoring of anticoagulant therapy by rural community pharmacists: description of successful outcomes. Aust J Rural Health (2004) 0.94
Pathogenesis of type 2 diabetes in South Asians. Eur J Endocrinol (2013) 0.93
The incidence of atrial fibrillation and the use of warfarin in Northland, New Zealand stroke patients. N Z Med J (2011) 0.93
Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models. PLoS One (2013) 0.93
Prevalence of atrial fibrillation in China and its risk factors. Biomed Environ Sci (2013) 0.92
Stroke risk factors, subtypes, and 30-day case fatality in Abuja, Nigeria. Niger Med J (2013) 0.92
Drug-drug interactions in hospitalized cardiac patients. J Young Pharm (2011) 0.91
Pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--in rats and dogs. Xenobiotica (2005) 0.91
Stroke risk and suboptimal thromboprophylaxis in Chinese patients with atrial fibrillation: would the novel oral anticoagulants have an impact? Int J Cardiol (2012) 0.91
Impact of educational intervention on the pattern and incidence of potential drug-drug interactions in Nepal. Pharm Pract (Granada) (2009) 0.91
Pattern of potential drug-drug interactions in diabetic out-patients in a tertiary care teaching hospital in Nepal. Med J Malaysia (2007) 0.90
The effect of pharmacist intervention and patient education on lipid-lowering medication compliance and plasma cholesterol levels. Can J Clin Pharmacol (2003) 0.90
Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison. Br J Clin Pharmacol (2014) 0.89
Benefits of a mobile, point-of-care anticoagulation therapy management program. Jt Comm J Qual Improv (2002) 0.88
A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation. J Thromb Thrombolysis (2014) 0.87
Bupropion-warfarin combination: a serious complication. Indian J Psychol Med (2013) 0.87
Ethnicity and stroke risk in patients with atrial fibrillation. Heart (2013) 0.86
Fatal association of mechanical valve thrombosis with dabigatran: a report of two cases. Chest (2013) 0.85
Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter? Clinicoecon Outcomes Res (2013) 0.85
South Africa's poor warfarin control raises questions of benefit above other anticoagulant therapies in atrial fibrillation. Cardiovasc J Afr (2011) 0.84
Bleeding and antidotes in new oral anticoagulants. Best Pract Res Clin Haematol (2013) 0.84
Predicting the quality of anticoagulation during warfarin therapy: the basis for an individualized approach. Chest (2013) 0.83
Stroke: a case series study in Nepal Medical College Teaching Hospital. Nepal Med Coll J (2006) 0.83
The role of evidence in the decision-making process of selecting essential medicines in developing countries: the case of Tanzania. PLoS One (2014) 0.82
Dabigatran and mechanical heart valves--not as easy as we hoped. N Engl J Med (2013) 0.82
Anticoagulation for atrial fibrillation: underutilization in a Brazilian tertiary outpatient clinic. Clin Cardiol (2004) 0.81
Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium. J Med Econ (2013) 0.81
Retrospective analysis of stroke and its risk factors at Nepal Medical College Teaching Hospital. Nepal Med Coll J (2006) 0.81
Comparative evaluation of warfarin utilisation in two primary healthcare clinics in the Cape Town area. Cardiovasc J Afr (2013) 0.81
Pharmacology of the new target-specific oral anticoagulants. J Thromb Thrombolysis (2013) 0.80
Dabigatran Use in the Real World: A Multihospital System Experience. J Pharm Pract (2013) 0.80
A combined pharmacometric analysis of dabigatran etexilate in healthy volunteers and patients with atrial fibrillation or undergoing orthopaedic surgery. Thromb Haemost (2012) 0.80
Prevalence of pulmonary tuberculosis among HIV infected persons in Pokhara, Nepal. J Nepal Health Res Counc (2012) 0.80
A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long‑term prevention of thromboembolic complications in patients with atrial fibrillation? Pol Arch Med Wewn (2012) 0.80
Novel oral anticoagulants in cardiovascular disease. J Cardiovasc Pharmacol Ther (2013) 0.80
Effect of nurse practitioner and pharmacist counseling on inappropriate medication use in family practice. Can Fam Physician (2012) 0.80
Thromboembolism in a patient with a mechanical mitral valve during anticoagulation with dabigatran etexilate. Ann Thorac Surg (2013) 0.79
Underutilization of anticoagulation therapy in chronic atrial fibrillation. Jpn Heart J (2001) 0.79
Patients satisfaction with warfarin and willingness to switch to dabigatran: a patient survey. J Thromb Thrombolysis (2014) 0.78
The evaluation of general practitioners' awareness/knowledge and adherence to the GOLD guidelines in a Shanghai suburb. Asia Pac J Public Health (2013) 0.78
Adverse Drug Reactions and Clinical Outcomes in Patients Initiated on Antiretroviral Therapy: A Prospective Cohort Study From Ethiopia. Drug Saf (2015) 2.01
Preference and resource utilization in elderly patients: InnoLet versus vial/syringe. Diabetes Res Clin Pract (2004) 0.98
Adherence to antiretroviral drug therapy in adult patients who are HIV-positive in Northwest Ethiopia: a study protocol. BMJ Open (2013) 0.91
Epithelial-mesenchymal transition as a fundamental underlying pathogenic process in COPD airways: fibrosis, remodeling and cancer. Expert Rev Respir Med (2014) 0.88
Adherence to Antiretroviral Therapy and Virologic Failure: A Meta-Analysis. Medicine (Baltimore) (2016) 0.88
Drug-related problems identified in post-discharge medication reviews for patients taking warfarin. Int J Clin Pharm (2011) 0.85
An investigation into drug-related problems identifiable by commercial medication review software. Australas Med J (2013) 0.84
A 12-month follow-up study of "RedUSe": a trial aimed at reducing antipsychotic and benzodiazepine use in nursing homes. Int Psychogeriatr (2011) 0.81
Effectiveness of a national approach to prescribing education for multiple disciplines. Br J Clin Pharmacol (2013) 0.79
An effective approach to decrease antipsychotic and benzodiazepine use in nursing homes: the RedUSe project. Int Psychogeriatr (2009) 0.78
Suboptimal anticoagulant management in patients after hospital initiation of warfarin. Aust Fam Physician (2004) 0.76
Increased selenium concentrations in seronorm trace elements serum (level 2). Clin Chem (2004) 0.76
Review of psychotropic medication in Tasmanian residential aged care facilities. Australas J Ageing (2010) 0.76
Adherence to management guidelines for childhood asthma in Australia. Aust Fam Physician (2015) 0.75
Doctor and pharmacist - back to the apothecary! Aust Health Rev (2009) 0.75
Under-use of bisphosphonates in rural elderly women who have sustained fractures. Aust J Rural Health (2006) 0.75